Resonance Specialties is seeking shareholder approval to buy a manufacturing facility from Kaygee Laboratories for Rs 29.98 crore. This move aims for vertical integration and secures production supply.
Resonance Specialties Ltd Acquires Manufacturing Facility for Rs 29.98 Crore
Resonance Specialties Ltd announced a postal ballot to obtain shareholder approval for acquiring a manufacturing facility in Mandideep, Madhya Pradesh, from Kaygee Laboratories Private Limited. Reader Takeaway: Vertical integration achieved; Rs 29.98 Cr acquisition; related party transaction scrutiny. ## What just happened Resonance Specialties Ltd is undertaking a postal ballot to get shareholder consent for purchasing a manufacturing facility. The facility, located at Mandideep, is currently owned by Kaygee Laboratories Private Limited (KLPL). The transaction value is Rs 29.98 crore, which is based on a slump sale. This acquisition represents 33.22% of the company's FY 2025-26 annual turnover. ## Why this matters This acquisition is aimed at achieving vertical integration for Resonance Specialties. The company currently manufactures chemical intermediates and APIs through a job work agreement with KLPL. By acquiring the facility, Resonance expects to ensure a continuous supply of production, improve operational control, and reduce costs associated with external manufacturing. ## The backstory The facility includes leasehold land, industrial buildings, plant and machinery, and relevant licenses. The transaction is significant as it involves a related party, with directors of Resonance Specialties also being directors at KLPL, and KLPL belonging to the same promoter group. An independent valuation report from S R Valuers supports the transaction value. ## What changes now Upon successful shareholder approval, Resonance Specialties will directly own and operate the manufacturing facility. This is expected to streamline operations and potentially improve margins by bringing production in-house. The company aims to reduce overall related party transactions in the long run through this integration. ## Risks to watch Investors will be watching the execution of the integration plan and the realization of expected operational efficiencies. The financing of the acquisition, partly from internal accruals and partly through borrowings, will also be a key factor. Shareholders should carefully assess the terms and valuation of this related party transaction. ## Peer comparison While specific peers and their recent facility acquisitions were not detailed in the filing, the move towards backward integration is a common strategy in the chemical and pharmaceutical sectors to secure supply chains and control costs. ## Context metrics (time-bound) The e-voting period for shareholders is from August 20, 2026, to September 18, 2026. The cut-off date for determining voting eligibility was August 14, 2026. ## What to track next Investors should track the outcome of the postal ballot and the subsequent integration process. The company's ability to achieve cost savings and production efficiencies from the acquired facility will be crucial.
